|Bid||0.17 x 1128700|
|Ask||0.17 x 500000|
|Day's Range||0.16 - 0.16|
|52 Week Range||0.09 - 0.28|
|PE Ratio (TTM)||-5.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Paratek, Cyclacel and Benitec stocks led a biotech surge on Tuesday, rising on strong trial results.
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.
A few biotech and pharma companies were on the move Tuesday. A few of the smaller caps made tremendous gains on the day, as the fourth-quarter earnings season is kicking off.